Supplementary
(A) Body weight in KRAS-mutant Lovo cell line xenografts treated by oral gavage with vehicle control, trametinib 3 mg/kg every other day, palbociclib 100 mg/kg daily, or combination trametinib and palbociclib at same dosing regimens. P < 0.002 for combination vs. control and combination vs. palbociclib on days 7-21 by Student's t-test. p < 0.03 for combination vs. trametinib on days 7-17. (B) Lovo cell line xenografts were treated with control chow or chow containing trametinib + palbociclib, and tumor volume was measured longitudinally. (C) Body weight in KRAS-mutant PDXs treated by oral gavage with vehicle control, trametinib 3 mg/kg every other day, palbociclib 100 mg/kg daily, or combination trametinib and palbociclib at same dosing regimens. P < 0.02 for combination vs. control, combination vs. trametinib, or combination vs. palbociclib on days 7-21 by Student's t-test.
